Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.295 CAD | 0.00% | 0.00% | -68.28% |
Apr. 24 | Antibe Therapeutics Inc. Announces Board Resignations | CI |
Apr. 19 | Antibe Therapeutics Seeks Extension of Stay of Proceedings | MT |
Business Summary
Number of employees: 11
Managers
Managers | Title | Age | Since |
---|---|---|---|
Alain Wilson
DFI | Director of Finance/CFO | - | 15-11-30 |
Chief Tech/Sci/R&D Officer | - | - | |
Ana Stegic
CTO | Chief Tech/Sci/R&D Officer | - | - |
Scott Curtis
COO | Chief Operating Officer | - | 15-12-31 |
Joseph Stauffer
CTO | Chief Tech/Sci/R&D Officer | 58 | 20-05-05 |
Investor Relations Contact | - | - | |
David Vaughan
PRN | Corporate Officer/Principal | 74 | 12-10-31 |
Corporate Officer/Principal | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 50 | 20-11-23 | |
Amal Khouri
BRD | Director/Board Member | - | 18-03-18 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 53,009,362 | 48,801,128 ( 92.06 %) | 0 | 92.06 % |
Company contact information
Antibe Therapeutics, Inc.
15 Prince Arthur Avenue
M5R 1B2, Toronto
+416-922-3460
http://www.antibethera.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-68.28% | 11.4M | |
-2.26% | 104B | |
+1.41% | 97.42B | |
+0.79% | 22.2B | |
-17.84% | 21.23B | |
-11.11% | 18.33B | |
-42.83% | 16.35B | |
-17.63% | 15.06B | |
+4.55% | 13.98B | |
+32.11% | 11.66B |
- Stock Market
- Equities
- ATE Stock
- Company Antibe Therapeutics Inc.